tetano
Editor, Senior Moderator
Influenza Other Respi Viruses. 2012 Apr 23. doi: 10.1111/j.1750-2659.2012.00367.x. [Epub ahead of print]
Safety and tolerability of a 6-week course of oseltamivir prophylaxis for seasonal influenza in children.
Reisinger K, Shu D, Cupelli L, Marcadis I, Dutkowski R.
Source
Primary Physicians Research, Pittsburgh, PA, USA. Gain Medical Centre, Coquitlam, BC, Canada. Hoffmann-La Roche Inc., Nutley, NJ, USA. Palm Beach Research Centre, Palm Beach FL, USA.
Abstract
Please cite this paper as: Reisinger et al. Safety and tolerability of a 6-week course of oseltamivir prophylaxis for seasonal influenza in children. Influenza and Other Respiratory Viruses DOI: 10.1111/j.1750-2659.2012.00367.x. In an open-label study, 49 children aged 1-12 years received oseltamivir (30-75 mg once daily depending on bodyweight) for 6 weeks for influenza prophylaxis. Seventeen participants reported 22 adverse events (AEs); in three participants, AEs were considered probably drug related (nausea or vomiting). No serious AEs were reported. The tolerability profile was similar to pooled safety data from treatment studies (duration of 5 days) in children.
? 2012 Blackwell Publishing Ltd.
PMID:
22520945
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22520945
Safety and tolerability of a 6-week course of oseltamivir prophylaxis for seasonal influenza in children.
Reisinger K, Shu D, Cupelli L, Marcadis I, Dutkowski R.
Source
Primary Physicians Research, Pittsburgh, PA, USA. Gain Medical Centre, Coquitlam, BC, Canada. Hoffmann-La Roche Inc., Nutley, NJ, USA. Palm Beach Research Centre, Palm Beach FL, USA.
Abstract
Please cite this paper as: Reisinger et al. Safety and tolerability of a 6-week course of oseltamivir prophylaxis for seasonal influenza in children. Influenza and Other Respiratory Viruses DOI: 10.1111/j.1750-2659.2012.00367.x. In an open-label study, 49 children aged 1-12 years received oseltamivir (30-75 mg once daily depending on bodyweight) for 6 weeks for influenza prophylaxis. Seventeen participants reported 22 adverse events (AEs); in three participants, AEs were considered probably drug related (nausea or vomiting). No serious AEs were reported. The tolerability profile was similar to pooled safety data from treatment studies (duration of 5 days) in children.
? 2012 Blackwell Publishing Ltd.
PMID:
22520945
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22520945